In the past week, PRPH stock has gone up by 11.60%, with a monthly gain of 0.90% and a quarterly plunge of -0.13%. The volatility ratio for the week is 4.35%, and the volatility levels for the last 30 days are 6.79% for ProPhase Labs Inc The simple moving average for the last 20 days is 11.51% for PRPH stock, with a simple moving average of -58.92% for the last 200 days.
Is It Worth Investing in ProPhase Labs Inc (NASDAQ: PRPH) Right Now?
Moreover, the 36-month beta value for PRPH is -0.44. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PRPH is 36.67M and currently, short sellers hold a 0.88% of that float. On June 17, 2025, PRPH’s average trading volume was 1.84M shares.
PRPH) stock’s latest price update
ProPhase Labs Inc (NASDAQ: PRPH) has seen a rise in its stock price by 17.41 in relation to its previous close of 0.33. However, the company has experienced a 11.60% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-17 that BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
Analysts’ Opinion of PRPH
Many brokerage firms have already submitted their reports for PRPH stocks, with H.C. Wainwright repeating the rating for PRPH by listing it as a “Buy.” The predicted price for PRPH in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on December 20, 2021 of the previous year 2021.
Dawson James gave a rating of “Buy” to PRPH, setting the target price at $25 in the report published on January 20th of the previous year.
PRPH Trading at 17.92% from the 50-Day Moving Average
After a stumble in the market that brought PRPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.69% of loss for the given period.
Stock Fundamentals for PRPH
Current profitability levels for the company are sitting at:
- -5.71 for the present operating margin
- -0.02 for the gross margin
The net margin for ProPhase Labs Inc stands at -7.88. The total capital return value is set at -1.24. Equity return is now at value -58.71, with -30.25 for asset returns.
Based on ProPhase Labs Inc (PRPH), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -0.71. The debt to equity ratio resting at 3.34. The interest coverage ratio of the stock is -11.53.
Currently, EBITDA for the company is -32.34 million with net debt to EBITDA at -0.74. When we switch over and look at the enterprise to sales, we see a ratio of 5.8. The receivables turnover for the company is 0.34for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
To wrap up, the performance of ProPhase Labs Inc (PRPH) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
